INCY

IncyteB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

35%

Probability

Target price

$120.00

+30.1% vs current

Most likely

Base case

45%

Probability

Target price

$109.00

+18.2% vs current

B-

Bear case

20%

Probability

Target price

$86.00

-6.8% vs current

AI sentiment snapshot

Latest data as of 2026-04-29

AI commentary

Sentiment is positive but not euphoric. Primary company materials support a strong quarter and a dense catalyst calendar, while recent post-print coverage framed results as an earnings and revenue beat. Even so, third-party coverage also described a mixed stock reaction, indicating that investors are still weighing guidance durability and product-transition risk. No reliable social-signal packet was provided, and the operating peer set is useful but imperfect, so confidence should lean on filings and company disclosures rather than crowd tone or broad peer extrapolation.

RankAlpha Sentiment Codex - 2026-04-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-15catalystQ1 2026 beat with guidance reaffirmed resets the post-print debateMedium impact

Incyte reported Q1 2026 revenue of $1.27 billion, net sales of $1.10 billion, GAAP EPS of $1.47 and non-GAAP diluted EPS of $1.81, while reaffirming full-year 2026 guidance across all categories; the company tied growth to Jakafi, Opzelura and newer hematology/oncology products, with cash rising to $4.0 billion as of March 31, 2026 [#8-K-2026-04-28] [#10-Q-2026-04-28].

2026-07-15eventJakafi XR and EU Opzelura AD decisions are the nearest regulatory bridge eventsMedium impact

Management said it expects a U.S. regulatory decision and potential commercial launch for Jakafi XR in mid-2026, and a second-half 2026 EU regulatory decision for Opzelura in moderate atopic dermatitis; both matter because they support diversification ahead of later patent-cycle concerns [#8-K-2026-04-28].

2026-11-30catalystPovorcitinib and broader late-stage pipeline remain the main durability driverHigh impact

The company highlighted positive Phase 3 vitiligo data for povorcitinib, FDA acceptance of the HS NDA, possible HS approval and launches from late 2026 into Q1 2027, and 10 Phase 3 studies underway; if execution holds, this is the clearest path to a more durable post-Jakafi growth profile [#8-K-2026-04-28] [#10-K-2026-02-10].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-29 • Updated nightlySource: Internal modelMethodology